☆ 4.8 Article

Plasma glial fibrillary acidic protein as a biomarker of disease progression in Parkinson's disease: a prospective cohort study

BMC MEDICINE (2023)

Related references

Note: Only part of the references are listed.

Article Clinical Neurology

Association of plasma biomarkers, p-tau181, glial fibrillary acidic protein, and neurofilament light, with intermediate and long-term clinical Alzheimer's disease risk: Results from a prospective cohort followed over 17 years

Hannah Stocker et al.

Summary: This study aimed to investigate the association between blood biomarkers and Alzheimer's disease (AD) risk. It found that GFAP may be an early biomarker for AD, while p-tau181 and NfL are associated with intermediate risk. The impact of cardiovascular health on p-tau181 and NfL should be considered in risk stratification.

ALZHEIMERS & DEMENTIA (2023)

Add to Collection

Article Clinical Neurology

Plasma GFAP associates with secondary Alzheimer's pathology in Lewy body disease

Katheryn A. Q. Cousins et al.

Summary: This study found that plasma GFAP may be sensitive to concomitant AD pathology in LBSD, especially accumulation of beta-amyloid plaques.

ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2023)

Add to Collection

Article Clinical Neurology

Neocortical Lewy Body Pathology Parallels Parkinson's Dementia, but Not Always

W. R. Wayne Martin et al.

Summary: This study investigates the relationship between Parkinson's disease (PD) with dementia and cortical proteinopathies. The study finds that neocortical Lewy bodies are commonly present in PD patients with dementia, but also appear in those without dementia. Other factors may contribute to PD dementia, aside from the classic neuropathological features.

ANNALS OF NEUROLOGY (2023)

Add to Collection

Article Neurosciences

Neurofilament light predicts worse nonmotor symptoms and depression in Parkinson's disease

Daniele Urso et al.

Summary: This study investigated the potential of cerebrospinal fluid (CSF) and serum neurofilament light (NfL) levels as biomarkers for predicting the progression of nonmotor symptoms (NMS) in Parkinson's disease (PD) patients. The findings showed that both CSF and serum NfL levels were associated with the progression of depression and anxiety in PD patients, with serum NfL showing stronger associations with NMS.

NEUROBIOLOGY OF DISEASE (2023)

Add to Collection

Article Immunology

Astrogliosis, neuritic microstructure, and sex effects: GFAP is an indicator of neuritic orientation in women

Ashesh A. Thaker et al.

BRAIN BEHAVIOR AND IMMUNITY (2023)

Add to Collection

Article Clinical Neurology

Neurofilament Light Chain Predicts Disease Severity and Progression in Multiple System Atrophy

Lingyu Zhang et al.

Summary: Plasma NFL levels are correlated with motor severity and progression in patients with MSA, but not with cognitive progression. It can serve as a reliable biomarker for monitoring the disease severity and progression of MSA.

MOVEMENT DISORDERS (2022)

Add to Collection

Review Clinical Neurology

Blood GFAP as an emerging biomarker in brain and spinal cord disorders

Ahmed Abdelhak et al.

Summary: Blood-derived biomarkers, such as glial fibrillary acidic protein (GFAP), hold promise in the diagnosis and prognosis of neurological diseases. However, there are limitations that hinder the widespread clinical use of GFAP as a biomarker.

NATURE REVIEWS NEUROLOGY (2022)

Add to Collection

Article Clinical Neurology

Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer's disease

Pratishtha Chatterjee et al.

Summary: This study found that GFAP and p-tau have good diagnostic and longitudinal monitoring potential in preclinical Alzheimer's disease. Combining GFAP with other proteins can improve diagnostic accuracy.

ALZHEIMERS & DEMENTIA (2022)

Add to Collection

Article Clinical Neurology

Plasma autoantibodies to glial fibrillary acidic protein (GFAP) react with brain areas according to Braak staging of Parkinson's disease

Eva Gschmack et al.

Summary: Idiopathic Parkinson's disease (PD) is characterized by progressive degeneration of the brain, and autoimmunity might play a role in its pathogenesis. A study found that anti-brain autoantibodies are common in both PD patients and healthy individuals. Glial fibrillary acidic protein (GFAP) was identified as a prominent autoantigen, and its autoimmunoreactivity in different brain areas correlated with the dissemination of PD pathology. It is hypothesized that GFAP autoantibodies, while physiological, may be involved in PD pathogenesis secondary to a blood-brain barrier leakage.

JOURNAL OF NEURAL TRANSMISSION (2022)

Add to Collection

Article Neurosciences

Plasma Neurofilament Light and p-tau181 and Risk of Psychosis in Parkinson's Disease

Lucy L. Gibson et al.

Summary: This study investigates the relationship between plasma NfL and p-tau181 with affective and psychotic symptoms in PD. The results suggest that baseline plasma NfL is associated with longitudinal changes in psychotic symptoms, but not with affective symptoms. Plasma p-tau181 concentration is not associated with psychotic or affective symptoms.

JOURNAL OF PARKINSONS DISEASE (2022)

Add to Collection

Article Neurosciences

Plasma p-tau181, neurofilament light chain and association with cognition in Parkinson's disease

Lucia Batzu et al.

Summary: Early identification of cognitive impairment in Parkinson's disease has important implications. This study found that plasma NfL concentration is associated with cognitive performance in PD patients and may serve as a biomarker for cognitive progression.

NPJ PARKINSONS DISEASE (2022)

Add to Collection

Review Neurosciences

Astrocytes in Neurodegeneration: Inspiration From Genetics

Jingxuan Huang et al.

Summary: The pathophysiology of neurodegenerative diseases is still unknown, but genetics and variants in astrocytes are implicated in the development of these diseases.

FRONTIERS IN NEUROSCIENCE (2022)

Add to Collection

Article Clinical Neurology

Astrogliosis in aging and Parkinson's disease dementia: a new clinical study with 11C-BU99008 PET

Mohamed A. Mohamed et al.

Summary: This imaging study in Parkinson's disease dementia found that astrogliosis is common with aging in specific regions. C-11-BU99008 PET was unable to differentiate these patients from healthy controls. The study used a specific PET radioligand to image reactive astrocytes in healthy controls and patients with Parkinson's disease dementia.

BRAIN COMMUNICATIONS (2022)

Add to Collection

Article Psychiatry

Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer's disease

Pratishtha Chatterjee et al.

Summary: The study found that plasma GFAP levels are elevated in cognitively normal older adults at risk of AD, indicating that astrocytic damage or activation may start from the pre-symptomatic stage of the disease and is associated with brain Aβ load. The potential of plasma GFAP to contribute to a diagnostic blood biomarker panel, along with plasma Aβ 1-42/Aβ 1-40 ratios, for cognitively normal older adults at risk of AD was highlighted by the observations from the present study.

TRANSLATIONAL PSYCHIATRY (2021)

Add to Collection

Article Multidisciplinary Sciences

Biomarkers of neurodegeneration and glial activation validated in Alzheimer's disease assessed in longitudinal cerebrospinal fluid samples of Parkinson's disease

Michael Bartl et al.

Summary: Except for alpha Syn, the additional biomarkers did not differentiate between PD and HC, and no significant longitudinal differences were shown, but most markers were able to predict cognitive decline in PD during follow-up.

PLOS ONE (2021)

Add to Collection

Article Clinical Neurology

APOE and MAPT Are Associated With Dementia in Neuropathologically Confirmed Parkinson's Disease

Jon-Anders Tunold et al.

Summary: The study found that the APOE epsilon 4 allele and MAPT H1-haplotype were associated with earlier development of dementia in patients with Parkinson's disease. These genetic variants play an important role in the etiology of Parkinson's disease dementia, providing potential implications for risk stratification and patient selection in clinical trials targeting cognitive decline.

FRONTIERS IN NEUROLOGY (2021)

Add to Collection

Article Clinical Neurology

Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum

Andrea L. Benedet et al.

Summary: The study suggests that plasma GFAP is a sensitive biomarker for detecting reactive astrogliosis and Aβ pathology in early stages of AD, outperforming CSF GFAP. Plasma GFAP levels accurately discriminate between Aβ-positive and Aβ-negative individuals, with higher accuracy than CSF GFAP.

JAMA NEUROLOGY (2021)

Add to Collection

Article Pharmacology & Pharmacy

Sex Differences in Behavioral Symptoms and the Levels of Circulating GFAP, Tau, and NfL in Patients With Traumatic Brain Injury

Dilorom Sass et al.

Summary: This study found sex differences in TBI patients, with females showing higher levels of biomarkers and behavioral symptoms compared to males. The relationship between biomarkers and behavioral outcomes was more evident in females than males, suggesting a need for further research on individualized treatment guidelines.

FRONTIERS IN PHARMACOLOGY (2021)

Add to Collection

Article Immunology

Glial Fibrillary Acidic Protein (GFAP): Neuroinflammation Biomarker in Acute Ischemic Stroke

Lisda Amalia

Summary: This study demonstrated a positive correlation between serum GFAP levels and the degree of neurological deficit in acute ischemic stroke patients. Higher GFAP levels were associated with higher NIHSS scores, indicating increased stroke severity and extent of brain damage. Additionally, a significant difference in serum GFAP levels was observed between ischemic stroke patients with large artery occlusion compared to small artery occlusion.

JOURNAL OF INFLAMMATION RESEARCH (2021)

Add to Collection

Article Clinical Neurology

Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment

Claudiaf Cicognola et al.

Summary: Plasma GFAP can detect AD pathology in patients with MCI and predict conversion to AD dementia, showing potential clinical utility.

ALZHEIMERS RESEARCH & THERAPY (2021)

Add to Collection

Article Clinical Neurology

Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer's disease

Joana B. Pereira et al.

Summary: The study suggests that plasma GFAP concentration is associated with brain amyloid-beta pathology but not tau aggregation in Alzheimer's disease. This indicates that plasma GFAP may be incorporated into current hypothetical models of Alzheimer's disease pathogenesis and used as a non-invasive tool to detect early astrocytosis.

BRAIN (2021)

Add to Collection

Article Medicine, Research & Experimental

Adenovirus-induced Reactive Astrogliosis Exacerbates the Pathology of Parkinson's Disease

Heeyoung An et al.

Summary: The study suggests that inducing reactive astrogliosis exacerbates PD pathologies, proposing virus combination as an advanced strategy for developing a new animal model of PD.

EXPERIMENTAL NEUROBIOLOGY (2021)

Add to Collection

Article Neurosciences

Longitudinal evolution of non-motor symptoms in early Parkinson's disease: a 3-year prospective cohort study

Ruwei Ou et al.

Summary: The study of global non-motor symptoms (NMS) in Chinese patients with Parkinson's disease (PD) showed an increase in the majority of NMS domains except for mood/apathy and sexual dysfunctions. The evolution of overall NMS in early PD was found to be mild and multidimensional, with a high NMS burden predicting faster motor progression of PD. This longitudinal study provides valuable insights into the progression of NMS in PD.

NPJ PARKINSONS DISEASE (2021)

Add to Collection

Article Clinical Neurology

Plasma biomarkers of astrocytic and neuronal dysfunction in early- and late-onset Alzheimer's

Fanny M. Elahi et al.

ALZHEIMERS & DEMENTIA (2020)

Add to Collection

Article Clinical Neurology

Plasma glial fibrillary acidic protein is raised in progranulin-associated frontotemporal dementia

Carolin Heller et al.

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2020)

Add to Collection

Article Clinical Neurology

Remote Blood Biomarkers of Longitudinal Cognitive Outcomes in a Population Study

Kumar B. Rajan et al.

ANNALS OF NEUROLOGY (2020)

Add to Collection

Article Geriatrics & Gerontology

Increased Cerebrospinal Fluid S100B and NSE Reflect Neuronal and Glial Damage in Parkinson's Disease

Ewa Papuc et al.

FRONTIERS IN AGING NEUROSCIENCE (2020)

Add to Collection

Article Neurosciences

Serum Glial Fibrillary Acidic Protein (GFAP) Is a Marker of Disease Severity in Frontotemporal Lobar Degeneration

Alberto Benussi et al.

JOURNAL OF ALZHEIMERS DISEASE (2020)

Add to Collection

Article Clinical Neurology

Combination of plasma amyloid beta(1-42/1-40)and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology

Inge M. W. Verberk et al.

ALZHEIMERS RESEARCH & THERAPY (2020)

Add to Collection

Article Clinical Neurology

Imidazoline 2 binding sites reflecting astroglia pathology in Parkinson's disease: an in vivo 11C-BU99008 PET study

Heather Wilson et al.

BRAIN (2019)

Add to Collection

Article Clinical Neurology

Blood NfL A biomarker for disease severity and progression in Parkinson disease

Chin-Hsien Lin et al.

NEUROLOGY (2019)

Add to Collection

Article Clinical Neurology

Association between plasma GFAP concentrations and MRI abnormalities in patients with CT-negative traumatic brain injury in the TRACK-TBI cohort: a prospective multicentre study

John K. Yue et al.

LANCET NEUROLOGY (2019)

Add to Collection

Article Neurosciences

Glial Fibrillary Acidic Protein in Serum is Increased in Alzheimer's Disease and Correlates with Cognitive Impairment

Patrick Oeckl et al.

JOURNAL OF ALZHEIMERS DISEASE (2019)

Add to Collection

Article Neurosciences

GFAP in early multiple sclerosis: A biomarker for inflammation

Rebecca Kassubek et al.

NEUROSCIENCE LETTERS (2017)

Add to Collection

Article Biochemistry & Molecular Biology

NADPH oxidase-derived H2O2 mediates the regulatory effects of microglia on astrogliosis in experimental models of Parkinson's disease

Liyan Hou et al.

REDOX BIOLOGY (2017)

Add to Collection

Review Clinical Neurology

MDS clinical diagnostic criteria for Parkinson's disease

Ronald B. Postuma et al.

MOVEMENT DISORDERS (2015)

Add to Collection

Article Biochemistry & Molecular Biology

Enteric GFAP expression and phosphorylation in Parkinson's disease

Thomas Clairembault et al.

JOURNAL OF NEUROCHEMISTRY (2014)

Add to Collection

Review Neurosciences

Astrocytic modulation of blood brain barrier: perspectives on parkinson's disease

Ricardo Cabezas et al.

FRONTIERS IN CELLULAR NEUROSCIENCE (2014)

Add to Collection

Article Psychiatry

The Beijing version of the montreal cognitive assessment as a brief screening tool for mild cognitive impairment: a community-based study

Jing Yu et al.

BMC PSYCHIATRY (2012)

Add to Collection

Article Clinical Neurology

Correlational study of the serum levels of the glial fibrillary acidic protein and neurofilament proteins in Parkinson's disease patients

Wen Su et al.

CLINICAL NEUROLOGY AND NEUROSURGERY (2012)

Add to Collection

Article Clinical Neurology

The natural history of treated Parkinson's disease in an incident, community based cohort

Jonathan R. Evans et al.

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2011)

Add to Collection

Article Biochemistry & Molecular Biology

Direct Transfer of α-Synuclein from Neuron to Astroglia Causes Inflammatory Responses in Synucleinopathies

He-Jin Lee et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2010)

Add to Collection

Review Clinical Neurology

Systematic Review of Levodopa Dose Equivalency Reporting in Parkinson's Disease

Claire L. Tomlinson et al.

MOVEMENT DISORDERS (2010)

Add to Collection

Article Clinical Neurology

CSF amyloid β 1-42 predicts cognitive decline in Parkinson disease

A. Siderowf et al.

NEUROLOGY (2010)

Add to Collection

Article Neurosciences

Astrocytic expression of Parkinson's disease-related A53T alpha-synuclein causes neurodegeneration in mice

Xing-Long Gu et al.

MOLECULAR BRAIN (2010)

Add to Collection

Article Clinical Neurology

The validity and reliability of Chinese frontal assessment battery in evaluating executive dysfunction among Chinese patients with small subcortical infarct

VCT Mok et al.

ALZHEIMER DISEASE & ASSOCIATED DISORDERS (2004)

Add to Collection

Review Clinical Neurology

The Unified Parkinson's Disease Rating Scale (UPDRS): Status and recommendations

CG Goetz et al.

MOVEMENT DISORDERS (2003)

Add to Collection

© Peeref 2019-2024. All rights reserved.